TB drug resistance in Canada: Supplementary data
![CCDR](/content/dam/phac-aspc/images/services/reports-publications/canada-communicable-disease-report-ccdr/ccdr-wordmark1140.jpg)
Volume 43-11, November 2, 2017: Antimicrobial resistance and One Health
Web exclusive
Tuberculosis drug resistance in Canada: 2006–2016 Supplementary data
V Gallant1, J Vachon1*, W Siu1
Affiliation
1 Centre for Communicable Disease and Infection Control, Public Health Agency of Canada, Ottawa, ON
Correspondence
Suggested citation
V Gallant, J Vachon, W Siu. Tuberculosis drug resistance in Canada: 2006–2016 Supplementary data. Can Commun Dis Rep. 2017;43(11). Web exclusive. https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2017-43/ccdr-volume-43-11-november-2-2017/tuberculosis-drug-resistance-canada-2006-2016-supplementary-data.html
Year | Total number of reported MTBC isolates | Resistant to one or more first-line drugs | Multidrug-resistant TBFootnote * | Extensively drug-resistant TBFootnote † | |||
---|---|---|---|---|---|---|---|
n | % | n | % | n | % | ||
2006 | 1,389 | 126 | 9.1 | 15 | 1.1 | 1 | 0.1 |
2007 | 1,267 | 133 | 10.5 | 11 | 0.9 | 0 | 0.0 |
2008 | 1,356 | 116 | 8.6 | 15 | 1.1 | 1 | 0.1 |
2009 | 1,331 | 127 | 9.5 | 18 | 1.4 | 0 | 0.0 |
2010 | 1,274 | 112 | 8.8 | 17 | 1.3 | 1 | 0.1 |
2011 | 1,319 | 139 | 10.5 | 18 | 1.4 | 1 | 0.1 |
2012 | 1,404 | 139 | 9.9 | 8 | 0.6 | 1 | 0.1 |
2013 | 1,371 | 112 | 8.2 | 14 | 1.0 | 1 | 0.1 |
2014 | 1,370 | 130 | 9.5 | 18 | 1.3 | 1 | 0.1 |
2015 | 1,339 | 139 | 10.4 | 22 | 1.6 | 0 | 0.0 |
2016 | 1,452 | 130 | 9.0 | 17 | 1.2 | 0 | 0.0 |
TOTAL | 14,872 | 1,403 | 9.4 | 173 | 1.2 | 7 | <0.1 |
Isolate characteristics | Reporting year | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | TOTAL | |||||||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Total number isolates tested | 1,389 | 100.0 | 1,267 | 100.0 | 1,356 | 100.0 | 1,331 | 100.0 | 1,274 | 100.0 | 1,319 | 100.0 | 1,404 | 100.0 | 1,371 | 100.0 | 1,370 | 100.0 | 1,339 | 100.0 | 1,452 | 100.0 | 14,872 | 100.0 |
Isolates tested that were susceptible | 1,263 | 90.9 | 1,134 | 89.5 | 1,240 | 91.4 | 1,204 | 90.5 | 1,162 | 91.2 | 1,180 | 89.5 | 1,265 | 90.1 | 1,259 | 91.8 | 1,240 | 90.5 | 1,200 | 89.6 | 1,322 | 91.0 | 13,469 | 90.6 |
Isolates showing any resistance to first-line drugs | ||||||||||||||||||||||||
Any resistance to isoniazid | 101 | 7.3 | 110 | 8.7 | 102 | 7.5 | 113 | 8.5 | 101 | 7.9 | 122 | 9.2 | 111 | 7.9 | 93 | 6.8 | 106 | 7.7 | 110 | 8.2 | 113 | 7.8 | 1,182 | 7.9 |
Any resistance to rifampin | 24 | 1.7 | 13 | 1.0 | 19 | 1.4 | 21 | 1.6 | 18 | 1.4 | 21 | 1.6 | 10 | 0.7 | 17 | 1.2 | 24 | 1.8 | 24 | 1.8 | 18 | 1.2 | 209 | 1.4 |
Any resistance to ethambutol | 12 | 0.9 | 23 | 1.8 | 13 | 1.0 | 17 | 1.3 | 10 | 0.8 | 9 | 0.7 | 4 | 0.3 | 10 | 0.7 | 6 | 0.4 | 10 | 0.7 | 10 | 0.7 | 124 | 0.8 |
Any resistance to pyrazinamideFootnote * | 16 | 1.5 | 27 | 2.7 | 22 | 2.1 | 18 | 1.7 | 25 | 2.4 | 28 | 2.3 | 33 | 2.8 | 26 | 2.2 | 30 | 2.6 | 38 | 3.4 | 38 | 3.0 | 301 | 2.0 |
Total number isolates resistant to one or more first-line TB drugs | 126 | 9.1 | 133 | 10.5 | 116 | 8.6 | 127 | 9.5 | 112 | 8.8 | 139 | 10.5 | 139 | 9.9 | 112 | 8.2 | 130 | 9.5 | 139 | 10.4 | 130 | 9.0 | 1,403 | 9.4 |
Monoresistant | 107 | 7.7 | 111 | 8.8 | 94 | 6.9 | 98 | 7.4 | 88 | 6.9 | 119 | 9.0 | 128 | 9.1 | 93 | 6.8 | 107 | 7.8 | 114 | 8.5 | 108 | 7.4 | 1,167 | 7.8 |
Multidrug resistant | 15 | 1.1 | 11 | 0.9 | 15 | 1.1 | 18 | 1.4 | 17 | 1.3 | 18 | 1.4 | 8 | 0.6 | 14 | 1.0 | 18 | 1.3 | 22 | 1.6 | 17 | 1.2 | 173 | 1.2 |
PolyresiFootnote †stant | 3 | 0.2 | 11 | 0.9 | 6 | 0.4 | 11 | 0.8 | 6 | 0.5 | 1 | 0.1 | 2 | 0.1 | 4 | 0.3 | 4 | 0.3 | 3 | 0.2 | 5 | 0.3 | 56 | 0.4 |
Extensively drug resistantFootnote ‡ | 1 | 0.1 | 0 | 0.0 | 1 | 0.1 | 0 | 0.0 | 1 | 0.1 | 1 | 0.1 | 1 | 0.1 | 1 | 0.1 | 1 | 0.1 | 0 | 0.0 | 0 | 0.0 | 7 | < 0.1 |
Isolate characteristics | Reporting year | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | ||||||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Isolates tested for resistance to INH, RMP, EMB & PZAFootnote * | 104 | 100.0 | 98 | 100.0 | 134 | 100.0 | 159 | 100.0 | 107 | 100.0 | 156 | 100.0 | 163 | 100.0 | 154 | 100.0 | 181 | 100.0 | 185 | 100.0 | 206 | 100.0 |
Isolates susceptible to all first-line TB drugs | 95 | 91.3 | 92 | 93.9 | 123 | 91.8 | 145 | 91.2 | 96 | 89.7 | 133 | 85.3 | 148 | 90.8 | 140 | 90.9 | 165 | 91.2 | 164 | 88.6 | 194 | 94.2 |
Monoresistant TB | ||||||||||||||||||||||
INH | 7 | 6.7 | 5 | 5.1 | 8 | 6.0 | 8 | 5.0 | 6 | 5.6 | 14 | 9.0 | 10 | 6.1 | 9 | 5.8 | 11 | 6.1 | 15 | 8.1 | 7 | 3.4 |
RMP | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 |
EMB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
PZA | 1 | 1.0 | 1 | 1.0 | 0 | 0 | 3 | 1.9 | 0 | 0 | 2 | 1.3 | 3 | 1.8 | 4 | 2.6 | 0 | 0 | 3 | 1.6 | 0 | 0 |
Subtotal - Monoresistant TB | 8 | 7.7 | 6 | 6.1 | 8 | 6.0 | 12 | 7.5 | 6 | 5.6 | 16 | 10.3 | 13 | 8.0 | 13 | 8.4 | 12 | 6.6 | 18 | 9.7 | 7 | 3.4 |
Polyresistant | ||||||||||||||||||||||
INH & EMB | 0 | 0.0 | 0 | 0.0 | 1 | 0.8 | 1.0 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 |
INH & EMB & PZA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.9 | 0 | 0 | 0 | 0 | 1 | 0.7 | 0 | 0 | 0 | 0 | 0 | 0 |
INH & PZA | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.6 | 1 | 0.9 | 0 | 0 | 1 | 0.6 | 0 | 0 | 0 | 0 | 1 | 0.5 | 0 | 0 |
Subtotal - Polyresistant | 0 | 0.0 | 0 | 0.0 | 1 | 0.7 | 2 | 1.3 | 2 | 1.9 | 0 | 0.0 | 1 | 0.6 | 1 | 0.6 | 0 | 0.0 | 1 | 0.5 | 1 | 0.5 |
Multidrug-resistant TBFootnote † | ||||||||||||||||||||||
INH & RMP | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA | 0 | 0.0 | 0 | 0.0 | 1 | 0.8 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 |
INH & RMP & EMB & PZA & SM & OFL & MOX | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & OFL & MOX & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & RBT | 0 | 0.0 | 0 | 0.0 | 1 | 0.8 | 0 | 0.0 | 1 | 0.9 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & SM | 1 | 1.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & SM & ETH & RBT & PAS | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 |
INH & RMP & ETH | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 |
INH & RMP & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 1.3 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 2 | 1.0 |
INH & RMP & PZA & SM & ETH | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & PZA & SM & OFL & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.9 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & PZA & SM & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.9 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & SM & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & SM & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Subtotal - Multidrug-resistant TB | 1 | 1.0 | 0 | 0.0 | 2 | 1.5 | 0 | 0.0 | 3 | 2.8 | 7 | 4.5 | 1 | 0.6 | 0 | 0.0 | 4 | 2.2 | 2 | 1.1 | 4 | 1.9 |
Extensively drug-resistant TBFootnote ‡ | ||||||||||||||||||||||
Subtotal - Extensively drug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Total number isolates resistant to one or more first-line TB drugs | 9 | 8.7 | 6 | 6.1 | 11 | 8.2 | 14 | 8.8 | 11 | 10.3 | 23 | 14.7 | 15 | 9.2 | 14 | 9.1 | 16 | 8.8 | 21 | 11.4 | 12 | 5.8 |
Isolate characteristics | Reporting year | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | ||||||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Isolates tested for resistance to INH, RMP, EMB & PZAFootnote *Footnote † | 275 | 100.0 | 231 | 100.0 | 254 | 100.0 | 239 | 100.0 | 201 | 100.0 | 194 | 100.0 | 254 | 100.0 | 213 | 100.0 | 264 | 100.0 | 231 | 100.0 | 217 | 100.0 |
Isolates susceptible to all first-line TB drugs | 257 | 93.5 | 210 | 90.9 | 230 | 90.6 | 215 | 90.0 | 182 | 90.6 | 170 | 87.6 | 231 | 90.9 | 194 | 91.1 | 230 | 87.1 | 199 | 86.2 | 196 | 90.3 |
Monoresistant TB | ||||||||||||||||||||||
INH | 7 | 2.6 | 13 | 5.6 | 18 | 7.1 | 22 | 9.2 | 16 | 8.0 | 21 | 10.8 | 21 | 8.3 | 19 | 8.9 | 24 | 9.1 | 27 | 11.7 | 15 | 6.9 |
RMP | 6 | 2.2 | 0 | 0.0 | 3 | 1.2 | 1 | 0.4 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 2 | 0.8 | 1 | 0.4 | 0 | 0.0 |
EMB | 3 | 1.1 | 4 | 1.7 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
PZA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 1 | 0.5 |
Subtotal - Monoresistant TB | 16 | 5.8 | 17 | 7.4 | 21 | 8.3 | 23 | 9.6 | 18 | 9.0 | 22 | 11.3 | 21 | 8.3 | 19 | 8.9 | 26 | 9.8 | 29 | 12.6 | 16 | 7.4 |
Polyresistant TB | ||||||||||||||||||||||
INH & EMB | 0 | 0 | 2 | 0.9 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 1 | 0.5 |
INH & PZA | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 2 | 0.8 | 0 | 0.0 | 2 | 0.9 |
Subtotal - Polyresistant TB | 0 | 0.0 | 2 | 0.9 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 2 | 0.8 | 1 | 0.4 | 3 | 1.4 |
Multidrug-resistant TBFootnote ‡ | ||||||||||||||||||||||
INH & RMP | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & KM & CM & ETH & RBT | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & PAS | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & RBT | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & ETH & RBT & PAS | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & KM & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & OFL & ETH & RBT & PAS | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & OFL & MOX | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 |
INH & RMP & EMB & SM & AK & KM & CM & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 |
INH & RMP & EMB & SM & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 1 | 0.4 | 0 | 0.0 |
INH & RMP & PZA & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & PZA & SM & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & PZA & SM & RBT & PAS | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & RBT | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 0.8 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & SM & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 1 | 0.5 |
Subtotal - Multidrug-resistant TB | 2 | 0.7 | 2 | 0.9 | 3 | 1.2 | 0 | 0.0 | 1 | 0.5 | 1 | 0.5 | 2 | 0.8 | 0 | 0.0 | 6 | 2.3 | 2 | 0.9 | 2 | 0.9 |
Extensively drug-resistant Footnote ** | ||||||||||||||||||||||
Subtotal - Extensively drug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Total number of isolates resistant to one or more first line drugs | 18 | 6.5 | 21 | 9.1 | 24 | 9.4 | 24 | 10.0 | 19 | 9.5 | 24 | 12.4 | 23 | 9.1 | 19 | 8.9 | 34 | 12.9 | 32 | 13.9 | 21 | 9.7 |
Isolate characteristics | Reporting year | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | ||||||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Isolates tested for resistance to INH, RMP, EMB and PZAFootnote * | 119 | 100.0 | 84 | 100.0 | 116 | 100.0 | 106 | 100.0 | 113 | 100.0 | 97 | 100.0 | 123 | 100.0 | 148 | 100.0 | 125 | 100.0 | 129 | 100.0 | 168 | 100 |
Isolates susceptible to all first-line TB drugs | 113 | 95.0 | 75 | 89.3 | 111 | 95.7 | 99 | 93.4 | 99 | 87.6 | 90 | 92.8 | 113 | 91.9 | 144 | 97.3 | 120 | 96.0 | 125 | 96.9 | 156 | 92.3 |
Monoresistant TB | ||||||||||||||||||||||
INH | 6 | 5.0 | 7 | 8.3 | 4 | 3.4 | 4 | 3.8 | 10 | 8.8 | 5 | 5.2 | 10 | 8.1 | 4 | 2.7 | 5 | 4.0 | 3 | 2.3 | 6 | 3.6 |
RMP | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
EMB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
PZA | 0 | 0.0 | 1 | 1.2 | 0 | 0.0 | 1 | 0.9 | 1 | 0.9 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 3 | 1.8 |
Subtotal - Monoresistant TB | 6 | 5.0 | 8 | 9.5 | 4 | 3.4 | 5 | 4.7 | 11 | 9.7 | 5 | 5.2 | 10 | 8.1 | 4 | 2.7 | 5 | 4.0 | 3 | 2.3 | 9 | 5.3 |
Polyresistant TB | ||||||||||||||||||||||
INH and EMB | 0 | 0.0 | 1 | 1.2 | 0 | 0.0 | 1 | 0.9 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH and PZA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.9 | 1 | 0.9 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 |
Subtotal - Polyresistant TB | 0 | 0.0 | 1 | 1.2 | 0 | 0.0 | 2 | 1.9 | 1 | 0.9 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 |
Multidrug-resistant TBFootnote † | ||||||||||||||||||||||
INH and RMP | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.9 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH, RMP, EMB, PZA, SM, AK, KM, CM, ETH and PAS | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH, RMP, EMB, SM, KM and RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 |
INH, RMP, PZA, ETH and RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 |
INH, RMP, PZA, SM and RBT | 0 | 0.0 | 0 | 0.0 | 1 | 0.9 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH, RMP and RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH, RMP, SM and RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.8 | 0 | 0.0 |
Subtotal - Multidrug-resistant TB | 0 | 0.0 | 0 | 0.0 | 1 | 0.9 | 0 | 0.0 | 1 | 0.9 | 2 | 2.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.8 | 2 | 1.2 |
Extensively drug-resistantFootnote ‡ | ||||||||||||||||||||||
INH, RMP, EMB, PZA, KM, OFL, ETH and RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.9 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Subtotal - Extensively drug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.9 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Total number of isolates resistant to one or more first line drugs | 6 | 5.0 | 9 | 10.7 | 5 | 4.3 | 7 | 6.6 | 14 | 12.4 | 7 | 7.2 | 10 | 8.1 | 4 | 2.7 | 5 | 4.0 | 4 | 3.1 | 12 | 7.1 |
Isolate characteristics | Reporting year | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | ||||||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Isolates tested for resistance to INH, RMP, EMB & PZAFootnote * | 3 | 100.0 | 5 | 100.0 | 3 | 100.0 | 10 | 100.0 | 9 | 100.0 | 5 | 100.0 | 4 | 100.0 | 3 | 100.0 | 6 | 100.0 | 7 | 100.0 | 9 | 100.0 |
Isolates susceptible to all first-line TB drugs | 3 | 100.0 | 5 | 100.0 | 3 | 100.0 | 10 | 100.0 | 7 | 77.8 | 5 | 100.0 | 3 | 75.0 | 2 | 66.7 | 6 | 100.0 | 5 | 71.4 | 0 | 0.0 |
Monoresistant TB | ||||||||||||||||||||||
INH | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 33.3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
RMP | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
EMB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
PZA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 25.0 | 0 | 0.0 | 0 | 0.0 | 1 | 14.3 | 0 | 0.0 |
Subtotal - Monoresistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 25.0 | 1 | 33.3 | 0 | 0.0 | 1 | 14.3 | 0 | 0.0 |
Polyresistant TB | ||||||||||||||||||||||
Subtotal - Polyresistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Multidrug-resistant TBFootnote † | ||||||||||||||||||||||
INH & RMP & PZA & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 14.3 | 0 | 0.0 |
Subtotal - Multidrug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 14.3 | 0 | 0.0 |
Extensively drug-resistantFootnote ‡ | ||||||||||||||||||||||
Subtotal - Extensively drug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Total number of isolates resistant to one or more first line drugs | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 25.0 | 1 | 33.3 | 0 | 0.0 | 2 | 28.6 | 0 | 0.0 |
Isolate characteristics | Reporting year | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | ||||||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Isolates tested for resistance to INH, RMP, EMB & PZA | 11 | 100.0 | 5 | 100.0 | 5 | 100.0 | 10 | 100.0 | 9 | 100.0 | 5 | 100.0 | 5 | 100.0 | 11 | 100.0 | 6 | 100.0 | 21 | 100.0 | 18 | 100.0 |
Isolates susceptible to all first-line TB drugs | 11 | 100.0 | 5 | 100.0 | 5 | 100.0 | 10 | 100.0 | 9 | 100.0 | 5 | 100.0 | 5 | 100.0 | 11 | 100.0 | 6 | 100.0 | 21 | 100.0 | 18 | 100.0 |
Monoresistant TB | ||||||||||||||||||||||
INH | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
RMP | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
EMB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
PZA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Subtotal - Monoresistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Polyresistant TB | ||||||||||||||||||||||
Subtotal - Polyresistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Multidrug-resistant TBFootnote * | ||||||||||||||||||||||
Subtotal - Multidrug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Extensively drug-resistantFootnote † | ||||||||||||||||||||||
Subtotal - Extensively drug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Total number of isolates resistant to one or more first line drugs | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Isolate characteristics | Reporting year | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | ||||||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Isolates tested for resistance to INH, RMP, EMB & PZA | 4 | 100.0 | 14 | 100.0 | 13 | 100.0 | 10 | 100.0 | 5 | 100.0 | 8 | 100.0 | 6 | 100.0 | 3 | 100.0 | 2 | 100.0 | 4 | 100.0 | 4 | 100.0 |
Isolates susceptible to all first-line TB drugs | 3 | 75.0 | 14 | 100.0 | 13 | 100.0 | 9 | 90.0 | 4 | 80.0 | 8 | 100.0 | 6 | 100.0 | 3 | 100.0 | 2 | 100.0 | 4 | 100.0 | 4 | 100.0 |
Monoresistant TB | ||||||||||||||||||||||
INH | 1 | 25.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 20.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
RMP | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 10.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
EMB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
PZA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Subtotal - Monoresistant TB | 1 | 25.0 | 0 | 0.0 | 0 | 0.0 | 1 | 10.0 | 1 | 20.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Polyresistant TB | ||||||||||||||||||||||
Subtotal - Polyresistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Multidrug-resistant TBFootnote * | ||||||||||||||||||||||
Subtotal - Multidrug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Extensively drug-resistantFootnote † | ||||||||||||||||||||||
Subtotal - Extensively drug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Total number of isolates resistant to one or more first line drugs | 1 | 25.0 | 0 | 0.0 | 0 | 0.0 | 1 | 10.0 | 1 | 20.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Isolate characteristics | Reporting year | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | ||||||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Isolates tested for resistance to INH, RMP, EMB & PZAFootnote * | 8 | 100.0 | 5 | 100.0 | 3 | 100.0 | 7 | 100.0 | 8 | 100.0 | 7 | 100.0 | 9 | 100.0 | 9 | 100.0 | 8 | 100.0 | 7 | 100.0 | 3 | 100.0 |
Isolates susceptible to all first-line TB drugs | 8 | 100.0 | 5 | 100.0 | 3 | 100.0 | 7 | 100.0 | 5 | 62.5 | 7 | 100.0 | 9 | 100.0 | 8 | 88.9 | 5 | 62.5 | 7 | 100.0 | 2 | 66.7 |
Monoresistant TB | ||||||||||||||||||||||
INH | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 12.5 | 0 | 0.0 | 0 | 0.0 | 1 | 11.1 | 3 | 37.5 | 0 | 0.0 | 0 | 0.0 |
RMP | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
EMB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
PZA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 12.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 33.3 |
Subtotal - Monoresistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 25.0 | 0 | 0.0 | 0 | 0.0 | 1 | 11.1 | 3 | 37.5 | 0 | 0.0 | 1 | 33.3 |
Polyresistant | ||||||||||||||||||||||
INH & PZA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 12.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Subtotal - Polyresistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 12.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Multidrug-resistant TBFootnote † | ||||||||||||||||||||||
Subtotal - Multidrug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Extensively drug-resistantFootnote ‡ | ||||||||||||||||||||||
Subtotal - Extensively drug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Total number of isolates resistant to one or more first line drugs | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 3 | 37.5 | 0 | 0.0 | 0 | 0.0 | 1 | 11.1 | 3 | 37.5 | 0 | 0.0 | 1 | 33.3 |
Isolate characteristics | Reporting year | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | |||||||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Isolates tested for resistance to INH, RMP, EMB & PZA | 28 | 100.0 | 37 | 100.0 | 25 | 100.0 | 51 | 100.0 | 50 | 100.0 | 71 | 100.0 | 64 | 100.0 | 65 | 100.0 | 42 | 100.0 | 66 | 100.0 | 35 | 100.0 | 33 | 100.0 |
Isolates susceptible to all first-line TB drugs | 28 | 100.0 | 37 | 100.0 | 24 | 96.0 | 51 | 100.0 | 49 | 98.0 | 70 | 98.6 | 62 | 96.9 | 65 | 100.0 | 42 | 100.0 | 66 | 100.0 | 33 | 94.3 | 33 | 100.0 |
Monoresistant TB | ||||||||||||||||||||||||
INH | 0 | 0.0 | 0 | 0.0 | 1 | 4.0 | 0 | 0.0 | 1 | 2.0 | 1 | 1.4 | 1 | 1.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 5.7 | 0 | 0.0 |
RMP | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
EMB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
PZA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Subtotal - Monoresistant TB | 0 | 0.0 | 0 | 0.0 | 1 | 4.0 | 0 | 0.0 | 1 | 2.0 | 1 | 1.4 | 2 | 3.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 5.7 | 0 | 0.0 |
Polyresistant TB | ||||||||||||||||||||||||
Subtotal - Polyresistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Multi-resistant TBFootnote * | ||||||||||||||||||||||||
Subtotal - Multidrug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Extensively drug-resistant TBFootnote † | ||||||||||||||||||||||||
Subtotal - Extensively drug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Total number of isolates resistant to one or more first line drugs | 0 | 0.0 | 0 | 0.0 | 1 | 4.0 | 0 | 0.0 | 1 | 2.0 | 1 | 1.4 | 2 | 3.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 5.7 | 0 | 0.0 |
Isolate characteristics | Reporting year | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | ||||||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Isolates tested for resistance to INH, RMP, EMB & PZAFootnote * | 567 | 100.0 | 538 | 100.0 | 479 | 100.0 | 488 | 100.0 | 496 | 100.0 | 507 | 100.0 | 493 | 100.0 | 511 | 100.0 | 457 | 100.0 | 480 | 100.0 | 505 | 100.0 |
Isolates susceptible to all first-line TB drugs | 504 | 88.9 | 466 | 86.6 | 427 | 89.1 | 428 | 87.7 | 456 | 91.9 | 454 | 89.6 | 429 | 87.0 | 458 | 89.6 | 407 | 89.1 | 421 | 87.7 | 453 | 89.7 |
Monoresistant TB | ||||||||||||||||||||||
INH | 39 | 6.9 | 50 | 9.3 | 33 | 6.9 | 39 | 8.0 | 27 | 5.4 | 39 | 7.7 | 45 | 9.1 | 27 | 5.3 | 30 | 6.6 | 30 | 6.3 | 43 | 8.5 |
RMP | 1 | 0.2 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 2 | 0.4 | 1 | 0.2 | 0 | 0.0 | 1 | 0.2 |
EMB | 0 | 0.0 | 1 | 0.2 | 1 | 0.2 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
PZA | 9 | 1.6 | 9 | 1.7 | 6 | 1.3 | 4 | 0.8 | 2 | 0.4 | 6 | 1.2 | 10 | 2.0 | 8 | 1.6 | 11 | 2.4 | 15 | 3.1 | 1 | 0.2 |
Subtotal - Monoresistant TB | 49 | 8.6 | 61 | 11.3 | 40 | 8.4 | 44 | 9.0 | 29 | 5.8 | 45 | 8.9 | 57 | 11.6 | 37 | 7.2 | 42 | 9.2 | 45 | 9.4 | 45 | 8.9 |
Polyresistant TB | ||||||||||||||||||||||
EMB & PZA | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & EMB | 3 | 0.7 | 1 | 0.2 | 2 | 0.4 | 3 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & EMB & PZA | 0 | 0.0 | 0 | 0.0 | 2 | 0.4 | 2 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & PZA | 0 | 0.0 | 2 | 0.4 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 1 | 0.2 | 2 | 0.4 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 |
Subtotal - Polyresistant TB | 3 | 0.5 | 4 | 0.7 | 4 | 0.8 | 5 | 1.0 | 1 | 0.2 | 0 | 0.0 | 1 | 0.2 | 3 | 0.6 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 |
Multidrug-resistant TBFootnote * | ||||||||||||||||||||||
INH & RMP | 2 | 0.4 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 |
INH & RMP & AK & CM & RBT | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & CM & RBT | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 |
INH & RMP & EMB & PZA & AK & CM & ETH & RBT | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & CM & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & ETH & RBT | 0 | 0.0 | 2 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & RBT | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 1 | 0.2 | 0 | 0.0 |
INH & RMP & EMB & PZA & RBT & PAS | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & AK & KM & CM & RBT & PAS | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 1 | 0.2 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 |
INH & RMP & EMB & PZA & SM & ETH & RBT & PAS | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & OFL & MOX & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & OFL & MOX & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 |
INH & RMP & EMB & PZA & SM & RBT | 0 | 0.0 | 1 | 0.2 | 1 | 0.2 | 1 | 0.2 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 3 | 0.6 | 0 | 0.0 |
INH & RMP & EMB & RBT | 1 | 0.4 | 1 | 0.2 | 1 | 0.2 | 2 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & SM & AK & CM | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & SM & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & SM & ETH & RBT & PAS | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & SM & KM & RBT & PAS | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & SM & OFL & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & SM & OFL & MOX & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & SM & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 1 | 0.2 | 0 | 0.0 | 1 | 0.2 |
INH & RMP & ETH & RBT | 2 | 0.4 | 0 | 0.0 | 1 | 0.2 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 |
INH & RMP & ETH & RBT & PAS | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & OFL & ETH & RBT & PAS | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & PAS | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 |
INH & RMP & PZA & ETH & RBT | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & PZA & SM & AK & KM & CM & ETH & RBT & PAS | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 |
INH & RMP & PZA & SM & ETH & RBT | 0 | 0.0 | 1 | 0.2 | 1 | 0.2 | 1 | 0.2 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 |
INH & RMP & PZA & SM & OFL & MOX & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & PZA & SM & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 1 | 0.2 | 1 | 0.2 | 0 | 0.0 | 1 | 0.2 |
INH & RMP & RBT | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 2 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & SM | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & SM & CM & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & SM & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 |
INH & RMP & SM & ETH & RBT & PAS | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & SM & KM & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & SM & OFL & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & SM & RBT | 0 | 0.0 | 0 | 0.0 | 3 | 0.6 | 1 | 0.2 | 1 | 0.2 | 1 | 0.2 | 1 | 0.2 | 2 | 0.4 | 1 | 0.2 | 5 | 1.0 | 0 | 0.0 |
Subtotal - Multidrug-resistant TB | 10 | 1.8 | 7 | 1.3 | 7 | 1.5 | 11 | 2.3 | 10 | 2.0 | 7 | 1.4 | 5 | 1.0 | 13 | 2.5 | 6 | 1.3 | 14 | 2.9 | 7 | 1.4 |
Extensively drug-resistant TBFootnote † | ||||||||||||||||||||||
INH & RMP & AK & CM & OFL & ETH & RBT | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & CM & OFL & ETH & RBT & PAS | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & KM & OFL & MOX & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & KM & OFL & MOX & ETH & RBT & PAS | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & KM & OFL & MOX & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 |
Subtotal - Extensively drug-resistant TB | 1 | 0.2 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 1 | 0.2 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 |
Total number of isolates resistant to one or more first line drugs | 63 | 11.1 | 72 | 13.4 | 52 | 10.9 | 60 | 12.3 | 40 | 8.1 | 53 | 10.5 | 64 | 13.0 | 53 | 10.4 | 50 | 10.9 | 59 | 12.3 | 52 | 10.3 |
Isolate characteristics | Reporting year | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | ||||||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Isolates tested for resistance to INH, RMP, EMB & PZA | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 100.0 | 1 | 100.0 | 3 | 100.0 | 0 | 0 | 0 | 0 | 2 | 100.0 | 2 | 100.0 | 4 | 100.0 |
Isolates susceptible to all first-line TB drugs | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 100.0 | 1 | 100.0 | 2 | 66.7 | 0 | 0 | 0 | 0 | 2 | 100.0 | 2 | 100.0 | 4 | 100.0 |
Monoresistant TB | ||||||||||||||||||||||
INH | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
RMP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
EMB | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
PZA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 1 | 33.3 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Subtotal - Monoresistant TB | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 1 | 33.3 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Polyresistant TB | ||||||||||||||||||||||
Subtotal - Polyresistant TB | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Multidrug-resistant TBFootnote * | ||||||||||||||||||||||
Subtotal - Multidrug-resistant TB | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Extensively drug-resistant TBFootnote † | ||||||||||||||||||||||
Subtotal - Extensively drug-resistant TB | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Total number of isolates resistant to one or more first line drugs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 1 | 33.3 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Isolate characteristics | Reporting year | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | ||||||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Isolates tested for resistance to INH, RMP, EMB and PZAFootnote * | 201 | 100.0 | 200 | 100.0 | 210 | 100.0 | 171 | 100.0 | 197 | 100.0 | 205 | 100.0 | 209 | 100.0 | 205 | 100.0 | 186 | 100.0 | 185 | 100.0 | 215 | 100 |
Isolates susceptible to all first-line TB drugs | 173 | 86.1 | 177 | 88.5 | 188 | 89.5 | 156 | 91.2 | 179 | 90.9 | 180 | 87.8 | 187 | 89.5 | 187 | 91.2 | 167 | 89.8 | 167 | 90.3 | 187 | 87.0 |
Monoresistant TB | ||||||||||||||||||||||
INH | 21 | 10.4 | 12 | 6.0 | 15 | 7.1 | 7 | 4.1 | 11 | 5.6 | 18 | 8.8 | 13 | 6.2 | 12 | 5.9 | 10 | 5.4 | 8 | 4.3 | 17 | 7.9 |
RMP | 1 | 0.5 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 |
EMB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
PZA | 4 | 2.0 | 4 | 2.0 | 4 | 1.9 | 2 | 1.2 | 5 | 2.5 | 6 | 2.9 | 9 | 4.3 | 4 | 2.0 | 7 | 3.8 | 6 | 3.2 | 9 | 4.2 |
Subtotal - Monoresistant TB | 26 | 12.9 | 17 | 8.5 | 19 | 9.0 | 9 | 5.3 | 16 | 8.1 | 24 | 11.7 | 22 | 10.5 | 16 | 7.8 | 17 | 9.1 | 15 | 8.1 | 26 | 12.1 |
Polyresistant TB | ||||||||||||||||||||||
INH and EMB | 0 | 0.0 | 3 | 1.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 |
INH and PZA | 0 | 0.0 | 1 | 0.5 | 1 | 0.5 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Subtotal - Polyresistant TB | 0 | 0.0 | 4 | 2.0 | 1 | 0.5 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 |
Multidrug-resistant TBFootnote † | ||||||||||||||||||||||
INH & RMP & EMB & ETH & RBT | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 |
INH & RMP & EMB & PZA & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & ETH | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & KM & ETH & RBT & PAS | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & PZA & SM & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & RBT | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & EMB & SM & RBT | 1 | 0.5 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 |
INH & RMP & PZA & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & PZA & SM & AK & KM & CM | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & PZA & SM & ETH & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 |
INH & RMP & PZA & SM & KM & CM & ETH | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 |
INH & RMP & SM & RBT | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 2 | 1.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 |
Subtotal - Multidrug-resistant TB | 2 | 1.0 | 2 | 1.0 | 2 | 1.0 | 6 | 3.5 | 1 | 0.5 | 1 | 0.5 | 0 | 0.0 | 1 | 0.5 | 2 | 1.1 | 2 | 1.1 | 2 | 0.9 |
Extensively drug-reistant TBFootnote ‡ | ||||||||||||||||||||||
INH, RMP, EMB, PZA, SM, AK, KM, CM, OFL, MOX, ETH and RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Subtotal - Extensively drug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Total number of isolates resistant to one or more first line drugs | 28 | 13.9 | 23 | 11.5 | 22 | 10.5 | 15 | 8.8 | 18 | 9.1 | 25 | 12.2 | 22 | 10.5 | 18 | 8.8 | 19 | 10.2 | 18 | 9.7 | 28 | 15.1 |
Isolate characteristics | Reporting year | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | ||||||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Isolates tested for resistance to INH, RMP, EMB & PZA | 58 | 100.0 | 60 | 100.0 | 81 | 100.0 | 77 | 100.0 | 54 | 100.0 | 66 | 100.0 | 72 | 100.0 | 71 | 100.0 | 63 | 100.0 | 50 | 100.0 | 65 | 100.0 |
Isolates susceptible to all first-line TB drugs | 57 | 98.3 | 59 | 98.3 | 79 | 97.5 | 72 | 93.5 | 51 | 94.4 | 62 | 93.9 | 68 | 94.4 | 69 | 97.2 | 60 | 95.2 | 49 | 98.0 | 62 | 95.4 |
Monoresistant TB | ||||||||||||||||||||||
INH | 1 | 1.7 | 1 | 1.7 | 2 | 2.5 | 3 | 3.9 | 2 | 3.7 | 4 | 6.1 | 1 | 1.4 | 1 | 1.4 | 0 | 0.0 | 0 | 0.0 | 2 | 3.1 |
RMP | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.6 | 0 | 0.0 | 0 | 0.0 |
EMB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
PZA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 3 | 4.2 | 1 | 1.4 | 1 | 1.6 | 1 | 2.0 | 1 | 1.5 |
Subtotal - Monoresistant TB | 1 | 1.7 | 1 | 1.7 | 2 | 2.5 | 3 | 3.9 | 2 | 3.7 | 4 | 6.1 | 4 | 5.6 | 2 | 2.8 | 2 | 3.2 | 1 | 2.0 | 3 | 4.6 |
Polyresistant TB | ||||||||||||||||||||||
INH & EMB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & PZA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.6 | 0 | 0.0 | 0 | 0.0 |
Subtotal - Polyresistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.6 | 0 | 0.0 | 0 | 0.0 |
Multidrug-resistant TBFootnote * | ||||||||||||||||||||||
INH & RMP & RBT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.9 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
INH & RMP & SM | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Subtotal - Multidrug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.3 | 1 | 1.9 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Extensively drug-resistant TBFootnote † | ||||||||||||||||||||||
Subtotal - Extensively drug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Total number of isolates resistant to one or more first line drugs | 1 | 1.7 | 1 | 1.7 | 2 | 2.5 | 5 | 6.5 | 3 | 5.6 | 4 | 6.1 | 4 | 5.6 | 2 | 2.8 | 3 | 4.8 | 1 | 2.0 | 3 | 4.6 |
Isolate characteristics | Reporting year | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | ||||||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Isolates tested for resistance to INH, RMP, EMB & PZAFootnote * | 2 | 100.0 | 2 | 100.0 | 7 | 100.0 | 3 | 100.0 | 5 | 100.0 | 2 | 100.0 | 1 | 100.0 | 1 | 100.0 | 4 | 100.0 | 3 | 100.0 | 2 | 100.0 |
Isolates susceptible to all first-line TB drugs | 2 | 100.0 | 2 | 100.0 | 7 | 100.0 | 3 | 100.0 | 5 | 100.0 | 2 | 100.0 | 1 | 100.0 | 1 | 100.0 | 4 | 100.0 | 3 | 100.0 | 2 | 100.0 |
Monoresistant TB | ||||||||||||||||||||||
Subtotal - Monoresistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Polyresistant TB | ||||||||||||||||||||||
Subtotal - Polyresistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Multidrug-resistant TBFootnote † | ||||||||||||||||||||||
Subtotal - Multidrug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Extensively drug-reistant TBFootnote ‡ | ||||||||||||||||||||||
Subtotal - Extensively drug-resistant TB | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Total number of isolates resistant to one or more first line drugs | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Reporting province/territoryFootnote * | Canada | Originating province/territory | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N.L. | P.E.I. | N.S. | N.B. | Que. | Ont. | Man. | Sask. | Alta. | B.C. | Y.T. | N.W.T | Nvt. | ||
N.L. | 18 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
N.S. | 7 | 0 | 4 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
N.B. | 9 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Que. | 215 | 0 | 0 | 0 | 0 | 215 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ont. | 536 | 0 | 0 | 0 | 0 | 3 | 504 | 0 | 0 | 0 | 0 | 0 | 0 | 29 |
Man. | 168 | 0 | 0 | 0 | 0 | 0 | 0 | 168 | 0 | 0 | 0 | 0 | 0 | 0 |
Sask. | 63 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 63 | 0 | 0 | 0 | 0 | 0 |
Alta. | 216 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 206 | 0 | 0 | 4 | 4 |
B.C. | 220 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 217 | 2 | 0 | 0 |
TOTAL | 1,452 | 18 | 4 | 3 | 9 | 218 | 505 | 168 | 65 | 206 | 217 | 2 | 4 | 33 |
Isolate characteristics | Canada | Originating province/territory | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N.L. | P.E.I. | N.S. | N.B. | Que. | Ont. | Man. | Sask. | Alta. | B.C. | Y.T. | N.W.T | Nvt. | ||
INH & RMP | 6 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 2 | 1 | 0 | 0 | 0 |
INH & RMP & EMB | 4 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
INH & RMP & EMB & PZA | 4 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
INH & RMP & PZA | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Total number of Multidrug-resistant TBFootnote * | 17 | 0 | 0 | 0 | 0 | 2 | 7 | 2 | 0 | 4 | 2 | 0 | 0 | 0 |
Extensively drug-resistant TBFootnote † | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Originating province/territory | Total number of reported MTBC Isolates | Resistant to one or more first-line drugs | Multidrug-resistant TBFootnote * | Extensively drug-resistant TBFootnote † |
|||
---|---|---|---|---|---|---|---|
Number | Percent (%) | Number | Percent (%) | Number | Percent (%) | ||
Ontario | 5,521 | 618 | 11.2 | 97 | 1.8 | 5 | 0.1 |
British Columbia | 2,573 | 259 | 10.1 | 21 | 0.8 | 0 | 0.0 |
Quebec | 2,187 | 237 | 10.8 | 21 | 1.0 | 1 | 0.0 |
Alberta | 1,647 | 152 | 9.2 | 24 | 1.5 | 0 | 0.0 |
Manitoba | 1,328 | 83 | 6.3 | 7 | 0.5 | 1 | 0.1 |
Saskatchewan | 717 | 29 | 4.0 | 2 | 0.3 | 0 | 0.0 |
Nunavut | 537 | 7 | 1.3 | 0 | 0.0 | 0 | 0.0 |
Newfoundland and Labrador | 106 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Nova Scotia | 74 | 8 | 10.8 | 0 | 0.0 | 0 | 0.0 |
Northwest Territories | 73 | 3 | 4.1 | 0 | 0.0 | 0 | 0.0 |
New Brunswick | 64 | 6 | 9.4 | 1 | 1.6 | 0 | 0.0 |
Yukon | 32 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Prince Edward Island | 13 | 1 | 7.7 | 0 | 0.0 | 0 | 0.0 |
Canada | 14,872 | 1,403 | 9.4 | 173 | 1.2 | 7 | 0.0 |
Age group and sex | Isolates reported | Resistant to one or more first-line drugs | Multidrug resistantFootnote * | Extensively drug resistantFootnote † | |||||
---|---|---|---|---|---|---|---|---|---|
Number | Percent (%) | Number | Percent (%) | Number | Percent (%) | Number | Percent (%) | ||
< 1 | Male | 1 | 0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Female | 1 | 0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Total | 2 | 0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
1 to 4 | Male | 5 | 0.3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Female | 6 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Unknown | 0 | 0.0 | 1 | 0.8 | 0 | 0.0 | 0 | 0.0 | |
Total | 11 | 0.8 | 1 | 0.8 | 0 | 0.0 | 0 | 0.0 | |
5 to 14 | Male | 11 | 0.8 | 1 | 0.8 | 0 | 0.0 | 0 | 0.0 |
Female | 11 | 0.8 | 3 | 2.3 | 1 | 5.9 | 0 | 0.0 | |
Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Total | 22 | 1.5 | 4 | 3.1 | 1 | 5.9 | 0 | 0.0 | |
15 to 24 | Male | 112 | 7.7 | 11 | 8.5 | 1 | 5.9 | 0 | 0.0 |
Female | 95 | 6.5 | 14 | 10.8 | 3 | 17.6 | 0 | 0.0 | |
Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Total | 207 | 14.3 | 25 | 19.2 | 4 | 23.5 | 0 | 0.0 | |
25 to 34 | Male | 126 | 8.7 | 8 | 6.2 | 2 | 11.8 | 0 | 0.0 |
Female | 160 | 11.0 | 18 | 13.8 | 2 | 11.8 | 0 | 0.0 | |
Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Total | 286 | 19.7 | 26 | 20.0 | 4 | 23.5 | 0 | 0.0 | |
35 to 44 | Male | 98 | 6.7 | 6 | 4.6 | 0 | 0.0 | 0 | 0.0 |
Female | 84 | 5.8 | 12 | 9.2 | 4 | 23.5 | 0 | 0.0 | |
Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Total | 182 | 12.5 | 18 | 13.8 | 4 | 23.5 | 0 | 0.0 | |
45 to 54 | Male | 104 | 7.2 | 11 | 8.5 | 1 | 5.9 | 0 | 0.0 |
Female | 71 | 4.9 | 5 | 3.8 | 1 | 5.9 | 0 | 0.0 | |
Unknown | 1 | 0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Total | 176 | 12.1 | 16 | 12.3 | 2 | 11.8 | 0 | 0.0 | |
55 to 64 | Male | 111 | 7.6 | 14 | 10.8 | 2 | 11.8 | 0 | 0.0 |
Female | 49 | 3.4 | 4 | 3.1 | 0 | 0.0 | 0 | 0.0 | |
Unknown | 1 | 0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Total | 161 | 11.1 | 18 | 13.8 | 2 | 11.8 | 0 | 0.0 | |
65 to 74 | Male | 88 | 6.1 | 1 | 0.8 | 0 | 0.0 | 0 | 0.0 |
Female | 75 | 5.2 | 2 | 1.5 | 0 | 0.0 | 0 | 0.0 | |
Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Total | 163 | 11.2 | 3 | 2.3 | 0 | 0.0 | 0 | 0.0 | |
75+ | Male | 135 | 9.3 | 12 | 9.2 | 0 | 0.0 | 0 | 0.0 |
Female | 106 | 7.3 | 7 | 5.4 | 0 | 0.0 | 0 | 0.0 | |
Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Total | 241 | 16.6 | 19 | 14.6 | 0 | 0.0 | 0 | 0.0 | |
Unknown | Male | 1 | 0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Female | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Total | 1 | 0.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Total | Male | 792 | 54.5 | 64 | 49.2 | 6 | 35.3 | 0 | 0.0 |
Female | 658 | 45.3 | 65 | 50.0 | 11 | 64.7 | 0 | 0.0 | |
Unknown | 2 | 0.1 | 1 | 0.8 | 0 | 0.0 | 0 | 0.0 | |
TOTAL | 1,452 | 100.0 | 130 | 100.0 | 17 | 100.0 | 0 | 0.0 | |
Page details
- Date modified: